title: Effect of lifestyle modification on serum chemerin concentration and its association with insulin sensitivity in overweight and obese adults with type 2 diabetes.
abstract: OBJECTIVE
  Chemerin, a recently identified adipokine, has been linked to adiposity, insulin resistance, metabolic syndrome risk factors and inflammation. Here, we evaluated whether a 12-week lifestyle intervention in overweight and obese adults with type 2 diabetes could significantly affect the average blood glucose and serum chemerin levels over time.
  
  
  METHODS
  Thirty-five overweight or obese subjects with type 2 diabetes were randomized to receive intensive lifestyle modification including supervised exercise sessions or usual care for 12 weeks. Anthropometric and clinical data were collected before the intervention and after 12 weeks.
  
  
  RESULTS
  Lifestyle intervention induced a significant decrease in HbA1c (-1·0 ± 0·5 vs 0·1 ± 0·6%, P < 0·001), BMI, total body fat content, serum lipocalin-2 and chemerin levels (-8·1 ± 21·6 vs + 8·2 ± 15·9 ng/ml, P = 0·021) and a significant increase in VO2 max after 12 weeks compared to the usual care group. Baseline chemerin levels were positively correlated with the homoeostasis model of assessment of insulin resistance (HOMA-IR), fasting insulin and the high-sensitivity C-reactive protein (hsCRP) and negatively correlated with insulin sensitivity index (ISI). Changes in the chemerin concentration during 12 weeks were independently negatively correlated with changes in ISI and positively correlated with changes in fasting plasma glucose, total cholesterol and lipocalin-2 levels.
  
  
  CONCLUSIONS
  A 12-week intensive lifestyle intervention significantly decreased serum chemerin level compared to usual care. Decrease in serum chemerin level was associated with improved insulin sensitivity, and this may be involved in the beneficial effects of lifestyle intervention in overweight and obese type 2 diabetic patients.
authors.affiliation: Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
authors.forename: So Hun
authors.initials: SH
authors.lastname: Kim
authors.forename: Seung Hwan
authors.initials: SH
authors.lastname: Lee
authors.forename: Ki Yong
authors.initials: KY
authors.lastname: Ahn
authors.forename: Dong Hoon
authors.initials: DH
authors.lastname: Lee
authors.forename: Young Ju
authors.initials: YJ
authors.lastname: Suh
authors.forename: Soon Gu
authors.initials: SG
authors.lastname: Cho
authors.forename: Yun Jin
authors.initials: YJ
authors.lastname: Choi
authors.forename: Dae Hyung
authors.initials: DH
authors.lastname: Lee
authors.forename: Seung Youn
authors.initials: SY
authors.lastname: Lee
authors.forename: Seong Bin
authors.initials: SB
authors.lastname: Hong
authors.forename: Yong Seong
authors.initials: YS
authors.lastname: Kim
authors.forename: Justin Y
authors.initials: JY
authors.lastname: Jeon
authors.forename: Moonsuk
authors.initials: M
authors.lastname: Nam
mesh_terms: D000209:Acute-Phase Proteins; D000328:Adult; D000886:Anthropometry; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004032:Diet; D005260:Female; D006706:Homeostasis; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008019:Life Style; D000071068:Lipocalin-2; D054834:Lipocalins / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D050177:Overweight / Q000097:blood*; D011518:Proto-Oncogene Proteins / Q000097:blood; D019707:Receptors, Chemokine / Q000097:blood*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000209:Acute-Phase Proteins; D001786:Blood Glucose; C102741:CMKLR1 protein, human; D007328:Insulin; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins; D019707:Receptors, Chemokine; D002097:C-Reactive Protein; D002784:Cholesterol